Anti-CD19 Antibody (4G7) 

Anti-CD19 Antibody (4G7) is an anti-human CD19 IgG1 monoclonal antibody. Anti-CD19 Antibody (4G7) reduces the killing effect of CAR T cells on Raji cells. Anti-CD19 Antibody (4G7) can be used for research on immunology. Anti-CD19 Antibody (4G7) is often used in flow cytometry. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977)^[1][2].

Mouse IgG1 kappa

Mouse IgG1 kappa, Isotype Control

Mouse

Anti-CD19 Antibody (4G7) (4 h) can block the killing of Raji cells by TanCAR T cells and reduce the secretion of IFN-γ and IL-2^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

12479  [NCBI]

P15391

Flow cytometry; Functional assays; Immunofluorescence

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

Liquid

Colorless to light yellow

[Anti-CD19 Antibody (4G7)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Flow Cytometry analysis of Raji cells labelling CD19 (red) with Anti-CD19 Antibody (anti-CD19) (HY-P990870). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Mouse IgG H&L (AF488) (HY-P8005) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Mouse IgG1 kappa (HY-P99977, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Grada Z, et al. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol Ther Nucleic Acids. 2013 Jul 9;2(7):e105.  [Content Brief]

  [2]. Rosa D, et al. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18544-9.  [Content Brief]